Dow Down0.22% Nasdaq Down0.25%

Spectrum Pharmaceuticals, Inc. (SPPI)

-NasdaqGS
8.18 Up 0.09(1.11%) 1:10PM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
Spectrum Pharmaceuticals, Inc.
11500 South Eastern Avenue
Suite 240
Henderson, NV 89052
United States - Map
Phone: 702-835-6300
Fax: 702-260-7405
Website: http://www.sppirx.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:226

Business Summary 

Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company’s commercialized drug products include FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; ZEVALIN injection for intravenous use as a prescription medication; and MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. It also develops BELEODAQ for the treatment of various hematological and solid tumors; Captisol-enabled MELPHALAN, an intravenous formulation of MELPHALAN for clinicians and patients in the multiple myeloma transplant setting; APAZIQUONE to treat non-muscle invasive bladder cancer; and SPI-2012 for the treatment of chemotherapy-induced neutropenia. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe and Japan. It has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan; collaboration agreement with Nippon Kayaku Co., Ltd.; licensing and collaboration agreement with TopoTarget A/S; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Spectrum Pharmaceuticals, Inc.

Corporate Governance 
Spectrum Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Oct 1, 2014 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 10; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. Rajesh C. Shrotriya M.D., 70
Chairman, Chief Exec. Officer, Chairman of Product Acquisition Committee and Chairman of Placement Committee
1.97M1.57M
Mr. Joseph W. Turgeon , 56
Pres and Chief Operating Officer
773.00K0.00
Mr. Kurt A. Gustafson , 46
Chief Financial Officer, Principal Accounting Officer and Exec. VP
508.00KN/A
Dr. Lee F. Allen M.D., Ph.D., 62
Chief Medical Officer
643.00K0.00
Mr. Shiv Kapoor ,
VP of Strategic Planning & Investor Relations
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders